The global GLP-1 receptor agonist market is projected to reach USD 78.4 billion by 2032, growing at a CAGR of 3.66%. The expansion is driven by increasing demand for effective metabolic disorder treatments, including diabetes and obesity management. As per MarkNtel Advisors,
Read More : https://www.prnewswire.co....